Auvelity for Agitation in Alzheimer’s Disease: A New FDA-Approved Treatment Option in Reno, Nevada

Agitation and hyperarousal are among the most distressing symptoms of Alzheimer’s disease—impacting patients, caregivers, and overall quality of life.

Until recently, treatment options were limited and often relied on off-label use of antipsychotics, which carry significant risks in older adults.

Now, a novel approach is emerging: Auvelity (dextromethorphan–bupropion) is gaining attention—and has received recent FDA approval for agitation in Alzheimer’s disease—marking a major shift in treatment strategy.